Information Update May 20, 2014
Movie by Plandai:
Plandaí and Cannabis – What is Our Role?
When Plandaí first announced its intention to produce a Phytofare™ Cannabinoid Extract, we were inundated with phone calls and emails—the majority of which wanted to know when and where they could buy some. Since that time, we’ve read different articles and blog posts speculating that Plandaí is growing marijuana on its South Africa plantation and importing its extract to Washington under the Diego Pellicer brand name.
With all of this misinformation out there, we felt it appropriate to “set the record straight” with respect to Plandaí and its involvement in the marijuana industry.
First, Plandaí is NOT presently producing any type of cannabis extract nor are we farming cannabis in South Africa, Washington or anywhere else. There are many reasons for this, but primarily we recognize that cannabis cultivation and extract production is illegal—everywhere—unless you have special permission from the government. Notwithstanding recent legislation in Washington and Colorado, growing, processing, possessing and selling marijuana in any form is still illegal on the federal level. Plandaí has no intention of crossing this line. Internationally, growing marijuana is illegal, especially in South Africa and other countries where we operate.
Initially, our attorneys believed we could set up a lab and begin testing in Washington. We set this process in motion by designing the equipment and reaching out to local scientists and researchers. We then determined that, if followed through upon, our activities could potentially violate federal laws and we immediately halted any efforts to produce an extract in the US.
With that being said, Plandaí believes that cannabis shows great medical potential. Unfortunately, very little testing has been done in a true, double-blind, controlled human clinical environment. Much of what we know is either anecdotal or backed by small lab-scale studies. We have developed the science that will allow us to produce a highly bioavailable cannabinoid complex. This new product should enable us to deliver a clinical dose of cannabinoids directly to human tissue and, theoretically, even cross the blood-brain barrier, enabling us to treat neuron disorders. Without testing, however, this is all theoretical.
Plandaí is actively working with several government agencies in hopes of being granted permission to commence testing our cannabinoid product. Once this permission is received, it will take us about ninety days to set up an extraction lab and produce the first extract. This extract will then be tested for purity and undergo a full chemical profile. Only then will be begin animal studies to determine what, if any, medicinal benefits are present. Favorable lab studies will eventually lead to human clinical trials but, again, only with proper government sanctioning.
We believe that favorable clinical trials will eventually pave the way for government acceptance. Especially for products like Plandaí’s which will have no psychoactive effects. Once we reach that point, we will have several decisions to make: Do we produce an extract locally? Do we license the technology to a third party? Do we farm our own product or purchase from a local grower? We cannot begin to answer these questions until we first have clinical results and then take account of the legal landscape at such future date.
The takeaway for our investors is that Plandaí remains committed to conducting ongoing research with a variety of different plants including cannabis and that this research will go forward as fast as the legal climate permits. Until such time, we remain committed to obeying the laws—federal, state, and international—while we continue to champion for changes to those laws and establish industry standards. We have a fiduciary responsibility to our shareholders to ensure that our company is built on a solid foundation of science, ethics, frugality, and adherence to the laws of the land.
We will continue to keep our shareholders aware of any changes to legislation and any government-approved dispensations we obtain.
Interview of CEO (Audio / February 14, 2012)
Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.
A/S : 500 million confirmed / State of Nevada
O/S : 134.300.000 (Febr. 6th, 2015)
Free Float: 66.300.000 (Febr. 6th, 2015)
Incorporated in: NV,USA - Year of Inc.: 2012 Transfer Agent
Signature Stock Transfer, Inc., Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093, 972-612-4120
LATEST NEWS January 9th, 2015
Plandai Biotechnology, Inc.'s CEO Discusses Company's Plans for 2015
NEW YORK, NY--(Marketwired - January 09, 2015) - Plandaí Biotechnology (PLPL) recently updated shareholders on a list of accomplishments reached in 2014, so Stock Market Media Group (SMMG), a research and content development investment relations firm, spoke with Plandaí's Chief Executive Officer, Roger Duffield, to discuss Plandaí's plans for 2015.
SMMG: First and foremost, can we get your reaction to the opening of your new production facility in South Africa and what does its completion mean for Plandaí in 2015?
Roger Duffield: "Well, opening the Senteeko facility is really the culmination of over a decade of research, sacrifice, and determination. Taking the initial concept that we could produce a highly bioavailable plant extract -- at a time when no one was even looking at the importance of bioavailability for nutraceuticals -- and then seeing it through to this point, has been an amazing journey that wouldn't have happened without the help and support of countless people. I get chills every time I visit Senteeko, drive thirty minutes on logging roads through thick forests, and then pass the gates to our estate and see the vast acres of tea with this amazing jewel of a factory sitting in the middle. I'm overwhelmed, excited, relieved, and deeply humbled all at the same time."
SMMG: What is the significance of Plandaí's shift from a research and development company to a biotech that produces and sells products?
Roger Duffield: "Let me answer by first stating that Plandaí will always be a research and development company. When you look at the pharmacopeia of medicinal plants, you can see that there are hundreds of potential future research products for us. And even with just green tea catechins, we could spend a lifetime just on different human clinical trials as we explore the vast potential of this amazing plant.
"But, from a practical standpoint, now that the factory is opened, we can start generating revenues and positive cash flows. This will allow us to operate without dilution or incurring additional debt, expand our products lines, and return value to our shareholders. "Operationally, it means that we now have a whole new business model with new logistics. When you stop to think about what it takes to sell a product like Phytofare®, it requires so many moving parts working in harmony. Growing the leaf, picking it properly, manufacturing, batch testing, packaging, tracking and quality control, shipping, customs. Then you have the sales aspect, which includes marketing, trade shows, literature. It's really quite a process that I think few people fully understand."
SMMG: In 2013 Plandaí announced its entrance into the cannabis research arena, in 2014, the company secured a licensing agreement with Diego Pellicer and then obtained a consent letter from the Minister of Health in Uruguay to begin growing cannabis and producing an extract for animal testing, so what can we expect in 2015?
Roger Duffield: "Our plan at this point is to establish the cannabis growing infrastructure in Uruguay this year with an expectation of having an extract ready for testing six to nine months after it comes online. Our initial goal of having a product market-ready by the end of 2014 proved unrealistic once we determined that current U.S. laws, even in states where marijuana is legalized, prohibited us from legally acquiring cannabis, producing an extract, and then testing it inside the U.S. "Our operation in Uruguay will allow us to better control the chemical profile and then conduct our research into various neural disorders in a safe, legal, and scientifically validated manner. Also, we will be able to establish standards for dosage and chemical profile, which has so far been very limited with respect to cannabis research."
SMMG: After releasing the data in 2014 from a human clinical trial performed at North West University in South Africa that showed Plandaí's Phytofare® Catechin Complex demonstrated ten times greater bioavailability over a generic catechin extract, what is next in the on-going research at North West University?
Roger Duffield: "Starting this month, the research team at North West University in South Africa, under the supervision of the Dean's office of the Faculty of Health Sciences and the inventor of the Pheroid® delivery system, Prof. Anne Grobler, will complete the third arm of the bioavailability study. This final phase will use the same 26 human subjects, but this time the study will incorporate the addition of Pheroid® to the Phytofare® extract. "We anticipate that adding the Pheroid® delivery system will increase the overall bioavailability while also opening up the potential to use our extracts in less controlled applications such as adding Phytofare® to other ingredients including topical creams and liquids, and in environments where you are less able to control exposure to outside influences such as UV light, which kills the antioxidants."North West University will also be conducting our human weight loss clinical trial, which will test the Phytofare® versus a placebo over 90 days and involving 120 patients. This trial will also be looking at a complete blood panel so we can identify from a medical standpoint the effects of catechins on everything from blood sugar to cholesterol. The results could potentially open entirely new fields of research."
SMMG: Any closing thoughts?
Roger Duffield: "2015 promises to be a productive year for Plandaí. With the completion of the new laboratory inside the Senteeko facility, we plan to produce our first citrus extract and then test its bioavailability followed by a human clinical trial to confirm improved respiratory benefits including symptom relief for sinus, colds and the flu. And, as always, we continue to explore the medical potential of other phytonutrients and expect to test new extracts throughout the year."
LOGAN, UT--(Marketwired - December 22, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced completion of the Company's production facility in South Africa. Further, the Company announced that samples from the first batch of Phytofare® Catechin Complex, which is derived from green tea, are being delivered to testing facilities for final profiling which will take place once vendors return from holiday. Additionally, samples are being sent to North West University to complete their clinical trials and to potential customers for evaluation. Over the coming days the factory will increase its manufacturing production with the expectation that the Company will then be ready to accept and fill customer orders.
Since beginning the Senteeko project in 2012, Plandaí has expended over $4.5 million in rehabilitating the tea estate and another $8.5 million in building the production facility, for a total investment of over $13 million.
Roger Duffield, Chief Executive Officer at Plandaí Biotechnology, commented, "Bringing a factory of this nature online has been a monumental task. We're proud that we've been able to build the factory onsite at the Senteeko plantation and that the clinical data has thus far supported our position that we can produce highly bioavailable, all-natural nutraceuticals."
The Senteeko factory encompasses approximately 75,000 sq. ft., is fully automated, and includes management offices and research facilities. At full capacity, the facility can process twenty tons of live plant material every day, averaging approximately eight tons of finished Phytofare® Catechin extract every month during the 8-month tea growing cycle.
Mr. Duffield added, "We currently have enough green tea ready for harvest to allow us to produce about six tons of Phytofare® per month based on estimated yields. We plan on bringing an additional 400 acres online this summer so that production can increase to full capacity. We will stockpile surplus Phytofare® for the dry season so that customer supply is not interrupted. During the summer period, when the tea is dormant, the factory has the ability to process lemons to produce Phytofare® Limonoid Glycoside extract with an estimated capacity of 15 tons per season."
Mr. Duffield concluded, "Commissioning the Senteeko factory has been a huge milestone for Plandaí. I personally could not be more proud of the Plandaí team and appreciative for the dedication, faith and sacrifices of so many people that helped realize the Plandaí vision."
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing raw materials on its farms in South Africa, to producing its proprietary Phytofare' extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Plandai Biotechnology Names Diego Pellicer Co-Founder and CannabisPioneer Jamen Shively as Vice President of Global Marketing
Recently Appointed Board Member Joins Management Team to Oversee Branding and Product Strategy
NEW YORK, NY, Feb 20, 2014 (Menafn - Marketwired via COMTEX) --Plandai Biotechnology, Inc. (otcqb:PLPL), a producer of highlybioavailable plant extracts for industries including health,wellness, nutraceutical, and pharmaceutical, announced today thatJamen Shively, a leading voice in the burgeoning marijuana industryand recently appointed Board Member of Plandai, has been named asVice President of Global Marketing.
As VP-Global Marketing, the company released, Mr. Shively will beresponsible for building brand awareness and marketing strategy forall of Plandai's operations including the Diego Pellicer(R) medicalcannabis line as well as the Phytofare(TM) botanical extracts such asthe Green Tea Catechin Complex and the Limonoid Glycoside Complex.
Roger Duffield, Chief Executive Officer of Plandai, commented on Mr.Shively's new position within the Company, "We're excited to bringJamen fully into the Plandai fold. He did a brilliant job buildingthe Diego Pellicer brand, and we're confident that he will build onthis experience as we launch the first of our products in the comingweeks. Our goal is to become the leading name in highly bioavailablebotanical extracts for both nutraceutical and pharmaceuticalapplications. Jamen has the vision and expertise to help further ustowards that end."
Mr. Shively stated, "I could not be more pleased to come aboardPlandai, first as a Director and now as a full-time member of themanagement team. Plandai is uniquely positioned in that it has noreal direct competition -- no one else in the market is selling highbioavailability plant extracts. Consumers are starting to demand morefrom their vitamins and supplements and asking to what extent are thebillions of dollars being spent on such products actually increasinghealth and wellness. My role with Plandai, as I see it, is to educatethe consumer that they need to demand more from their supplementswhile also telling the Plandai story. We have a unique opportunitywith Plandai's technology to fundamentally change how we addresswellness, health and prevention through natural, botanicalsolutions."
He added, "I am also extremely excited about the application ofPlandai's technologies to cannabis, which I believe willrevolutionize the application of cannabis to preventive andtherapeutic health, under the Diego Pellicer brand. This is theopportunity of a lifetime for me and for my colleagues at Plandai tochange the world by improving the health and wellness of mankindthrough 100% natural plant extracts. We are unlocking the potentialof nature's plant nutrients for humans and animals alike."
Jamen Shively, age 45, has a background in engineering and marketing,with specialties in artificial intelligence, the modeling andoptimization of complex networks, and the creation and positioning ofnew categories of products and services. Jamen co-founded DiegoPellicer Inc. in 2012 and built the brand from zero to the #1 mostrecognized brand of cannabis in the world in less than one year.Prior to founding Diego Pellicer, Jamen was a Corporate StategyManager for Microsoft from 2003 to 2009, where he focused on thecreation and development of new categories of software products andonline services. Preceding his Microsoft career he headed ShivelyInternational Inc., which built and operated both cybercafes andeducational computer centers in Mexico. Just prior to founding DiegoPellicer Inc., Jamen founded and headed the online marketplace forthe specialty food industry, Findood, winning first place in theNorthwest Entrepreneur Network's First Look Forum Competition for thetop new startup in 2010. Jamen completed his undergraduate work atU.C. Berkeley in Civil Engineering, and did graduate work at M.I.T.and U.C. Berkeley in Civil Engineering and Materials Science. He is aFellow of the National Science Foundation.
For press releases please visit: www.plandaibiotech.com/press-release.html
_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________ Management Team
President, Chief Executive officer and member of the Board of Directors
Vice-President and Global Director: Marketing
Chief Financial Officer and member of the Board of Directors
Investor Relations and member of the Board of Directors
Address: 2226 Eastlake Ave E, #156
Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website: http://www.plandaibiotech.com Email: Info@plandaibiotech.com
LIST OF RESEARCHES, COVERAGE, ETC. : http://www.cpreports.com/2013/05/22/ray-dirks-research-plandai-biotechnology-plpl-may-23-2013-by-ray-dirks/
............................... " Ray Dirks Research is projecting price targets for Plandaí Biotechnology, Inc. of $1.00 for the Short Term (6 to 9 Months) and $3.00 for the Long Term (1 to 3 Years)." http://www.goldmanresearch.com/Search.html?ordering=&searchphrase=all&searchword=plandai ................................ "As commercialization and further testing occurs, the shares should approach the $2.00 level in 2013." http://www.otcjournal.com ..................".....I've always had a 2013 price target on PLPL of $1.00. Based on the last 10 days, it looks like I'll be right on this one. I hope you own PLPL." http://www.stockmarketmediagroup.com/wp-content/uploads/2013/04/Plandai-Biotechnology-Inc.-PLPL-Research-Report.pdf
PLANDAI BIOTECHNOLOGY at Africa